← Back to all trials
Completed
NCT07209865
68Ga-P16-093 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI
Conditions: Prostate Cancer (Adenocarcinoma)
Sex: Male
Ages: 18 Years – 80 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 82
Sponsor: First Affiliated Hospital of Fujian Medical University
Location: Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University Fuzhou Fujian
Summary
68Ga-P16-093 is a novel radiotracer targeting PSMA. In this study, we investigated the diagnostic efficacy of 68Ga-P16-093 PET imaging (PET/CT or PET/MRI) in patients with newly diagnosed, treatment-naive prostate cancer, and performed a head-to-head comparison with multi-parameter magnetic resonance imaging (mpMRI).
Eligibility Criteria
Inclusion Criteria:
* Biopsy-confirmed adenocarcinoma of the prostate.
* No anti-tumor treatment received prior to the PET imaging.
* Subjects provide signed informed consent and confirm that they are able and willing to comply with all protocol requirements.
* Radical prostatectomy scheduled within 28 days after PET imaging.
Exclusion Criteria:
* Patients with other malignant tumors
* Subjects with any medical condition or other circumstance that, in the opinion of the investigator, compromise obtaining reliable data, achieving study objectives, or completion.
Source: ClinicalTrials.gov (NCT07209865). StuddyBuddy aggregates publicly available trial information.